TAK-875

TAK-875

A GPR40 agonist in Phase-III trials, which activates a receptor that stimulates and regulates insulin production, enhancing insulin secretion in response to changes in serum glucose levels. It has little effect on insulin secretion when serum glucose is normal, and may reduce the risk of hypoglycaemia.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Takeda Pharmaceutical, a Japan-based pharmaceutical company, has decided to voluntarily terminate the development activities of its type 2 diabetes investigational drug, fasiglifam (TAK-875), it was reported on Friday.
The oral, highly potent, and selective free fatty acid receptor 1 agonist TAK-875 significantly improved glycemic control in patients with type 2 diabetes without increasing treatment-emergent hypoglycemic events in a phase II, randomized, controlled trial comparing TAK-875, glimepiride, and placebo.
At weeks 4, 8, and 12 of treatment, all of the 303 patients who were randomized to receive treatment with TAK-875 at doses ranging from 6.25 to 200 mg once daily, as well as all of the 62 patients randomized to receive treatment with 4 mg glimepiride (a sulphonylurea that acts as an insulin secretagogue) once daily, achieved significant least-squares mean reductions from baseline in hemoglobin Alc, compared with the 61 patients randomized to a placebo group.
Additionally, the percentage of patients reaching the American Diabetes Association target of Hb[A.sub.1c] less than 7.0% by 12 weeks was generally similar in the 25- to 200-mg TAK-875 and glimepiride groups, and changes, relative to the placebo group, were significant, they said.
About 2% and 3% of the TAK-875 patients and the placebo patients, respectively, had treatment-emergent hypoglycemic events during treatment, compared with 19% of the glimepiride patients, and the events were mild to moderate in intensity in all groups.
Burant and his colleagues promise to raise many questions about the potential of TAK-875 in the treatment of type 2 diabetes, according to Dr.
TAK-875 appeared to have no effect on insulin resistance in this study.
18 October 2011 - Japan's Takeda Pharmaceutical Company Limited (TYO:4502) said today it had commenced a Phase III clinical study programme for its investigational Type 2 diabetes therapy TAK-875.
The programme will be carried out across the US, Latin America, and Europe, Takeda said, noting that TAK-875 is the first GPR40 agonist to reach late stage (Phase III) clinical development.
M2 PHARMA-September 12, 2011-Takeda advances TAK-875 into Phase III studies for Type 2 diabetes treatment(C)2011 M2 COMMUNICATIONS
12 September 2011 - Japanese Takeda Pharmaceutical Company Limited (TYO:4502) said today it had advanced TAK-875 into Phase III studies for the treatment of Type 2 diabetes in Japan.